Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

6 evidence topics · 4 sources

Background immunosuppressive therapy at baseline in the phase 2 trial
CharacteristicPlacebo (N=22)Claseprubart 300 mg every 2 weeks (N=21)Claseprubart 600 mg every 2 weeks (N=22)
Baseline corticosteroid use, n (%)“19 (86%)”“17 (81%)”“20 (91%)”
Number of immunosuppressive therapies at baseline: 1, n (%)“11 (50%)”“10 (48%)”“12 (55%)”
Number of immunosuppressive therapies at baseline: more than 1, n (%)“11 (50%)”“11 (52%)”“10 (45%)”
Neonatal Fc receptor blocker use in prior 24 months, n (%)“0 (0%)”“1 (5%)”“0 (0%)”
Prior complement inhibitor use, n (%)“0 (0%)”“0 (0%)”“0 (0%)”
Prior thymectomy, n (%)“8 (36%)”“6 (29%)”“7 (32%)”